Delivery Order SPE2DB25D3012-SPE2DB25FWWCH

Award Date 3/13/25
Potential Completion Date 3/14/25
Potential Value $112K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,067.27, is for the delivery of dapagliflozin 10 mg tablets. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of October 22, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,506.68 firm fixed-price contract is for the delivery of dapagliflozin 10 mg tablets. The contract has an ultimate completion date of November 13, 2024 and was awarded on November 12, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support...
This federal contract award, valued at $7,063.53, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DAPAGLIFLOZIN 10 MG TABLET 30S, a pharmaceutical product, with a performance period extending to February 25, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Dapagliflozin 10 mg tablets. The $5,061.60 Firm Fixed Price contract has a completion date of February 21, 2025 and is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,464.90, is for the delivery of 4564986974 - Dapagliflozin 10 mg tablets in 30-count packages. The contract has a firm fixed price and is set to expire on June 25, 2024. This order is associated with a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,754.38 firm fixed-price delivery order is for the supply of the drug Dapagliflozin 10 mg tablets. The award is associated with a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Dapagliflozin 10 mg tablets, which are used to treat type 2 diabetes. The contract has a ceiling value of $13,655.93 and a completion date of July 12, 2024. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp., a major pharmaceutical distributor, for the supply of dapagliflozin 10 mg tablets. The contract is a firm fixed-price agreement with a ceiling value of $1,614.94 and a period of performance through July 2024. This delivery order is likely part of a larger Indefinite Delivery Contract (IDC) the company holds with DLA Troop Support Medical, valued up to $999,999,999, for providing a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, a Delivery Order under a larger Indefinite Delivery Contract (IDC), is for the supply of dapagliflozin 10 mg tablets, a medication used to treat diabetes. The award has a ceiling value of $5,518.03 and a period of performance through January 28, 2025. The contract is a Firm Fixed Price arrangement and does not...
This federal contract award, valued at $9,503.35, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of dapagliflozin 10 mg tablets, a medication used to treat diabetes. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
  • SPE2DB25D3012
    Indefinite Delivery Contract
  • SPE2DB25D3012-SPE2DB25FWWCH
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $111,849.97, is for the delivery of dapagliflozin 10 mg tablets over a period ending on March 14, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition.

Generated 6/12/25, 10:18 AM